Amylyx Pharmaceuticals, Inc. AMLX

29.49 (0.65) (2.16%) as of 25 Sep
Market cap
$3.8B
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
11.86 17.52 13.98 13.34
Current Ratio
12.12 17.85 14.27 13.70
Net Debt/EBITDA
5.35 6.32 8.44 9.26
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.72 0.89 0.85 0.88
Capex/Depreciation
0.03 7.83 0.09 0.02
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.28) (0.33) (0.30) (0.33)
Capex per Share
0.00 (0.04) 0.00 0.00
Free Cash Flow per Share
(0.28) (0.37) (0.30) (0.33)
Cash per Share
2.26 2.53 3.35 3.69
Shareholders Equity per Share
2.15 2.47 3.23 3.56
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
2.15 2.47 3.23 3.56
Free Cash Flow
(31.45) (40.88) (27.99) (30.39)
Working Capital
235.19 269.06 300.98 327.59
Capital Expenditures
(0.03) (4.00) (0.09) (0.02)
Net Current Asset Value
230.94 264.58 296.29 322.64
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Other line items
Average Receivables
— — 0.27 0.93
Average Payables
4.41 4.17 3.23 3.41
Average Assets
229.58 256.64 263.14 306.73
Average Common Equity
203.52 237.29 235.01 264.10

Fold the line items

Columns are period end dates